Holman, R. R, Bethel, M. A, Chan, J. C, Chiasson, J. L, Doran, Z., Ge, J., Gerstein, H. C, Huo, Y., McMurray, J. J, Ryden, L., Liyanage, W., Schröder, S., Tendera, M., Theodorakis, M. J, Tuomilehto, J., Yang, W., Hu, D. & Pan, C. (2014). Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal,168(1), 23-29. United States: Mosby Inc.. Retrieved from https://doi.org/10.1016/j.ahj.2014.03.021
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus ( T2DM ). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
Mary MacKillop Institute for Health Research
Access may be restricted.